Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?The Motley Fool • 09/22/26
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?The Motley Fool • 09/22/26
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher24/7 Wall Street • 09/21/26
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?The Motley Fool • 09/18/26
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher24/7 Wall Street • 09/17/26
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatientsGlobeNewsWire • 09/14/26
Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC's ‘Final Trades'Benzinga • 08/31/26
BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And MoreSeeking Alpha • 08/28/26
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat24/7 Wall Street • 08/28/26
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineBusiness Wire • 08/27/26
Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?24/7 Wall Street • 08/25/26
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.24/7 Wall Street • 08/25/26
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips24/7 Wall Street • 08/24/26
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session24/7 Wall Street • 08/21/26